MEDICAL NEWS & POLICY
Healthcare updates
Medical news and healthcare policy from the United States, Europe and China, covering new treatments, research and access to specialist care.
Read the latest briefings below. Each includes publication dates and links to the original reports; older developments are identified as background.
FDA Approves Bepirovirsen for Selected Adults With Chronic Hepatitis B
The October 20 US decision includes defined laboratory criteria, use alongside existing antivirals and important safety monitoring.
Read the update →Briefing published 20 October 2026FDA Grants Accelerated Approval for a Biomarker-Defined Rectal Cancer Treatment
The October 19 US decision covers dostarlimab for a defined group of adults with locally advanced rectal cancer.
Read the update →Briefing published 19 October 2026FDA Lists Traditional Approval for Keytruda’s TMB-High Cancer Indication
The FDA conversion table records October 16, 2026 for a specific tumor mutational burden-high indication, following accelerated approval in 2020.
Read the update →Briefing published 17 October 2026EMA Confirms Refusal of Yartemlea After Re-examination
The October 15 committee opinion concerns a serious stem-cell transplant complication. EMA published its updated explanation on October 16.
Read the update →Briefing published 16 October 2026EMA Recommends Rasonque for Advanced Pancreatic Cancer
The October 15 recommendation concerns previously treated metastatic pancreatic cancer. An EU committee opinion, US approval and local access are separate steps.
Read the update →Briefing published 15 October 2026FDA Expands Anktiva Approval for Bladder Cancer
The US bladder cancer approval now includes high-grade papillary-only tumors. In China, officials set priorities for sharing medical imaging records.
Read the update →Briefing published 13 October 2026EMA Publishes Ocrevus Liver Safety Update
A European safety communication highlights liver injury risks with the multiple sclerosis medicine and monitoring before and during treatment.
Read the update →Briefing published 12 October 2026FDA Approves Pritelivir for Hard-to-Treat Herpes Infections
The October 9 US approval covers certain immunocompromised adults whose herpes simplex lesions have not responded to other antiviral therapies.
Read the update →Briefing published 10 October 2026FDA Approves Atezolizumab Combination for Stage III dMMR Colon Cancer
The October 8 US approval covers a defined group after surgery. Other regulators participating in Project Orbis are still reviewing the application.
Read the update →Briefing published 9 October 2026US Insurers Face New Rules on Healthcare Price Transparency
New US rules address insurers’ public pricing files and telephone cost estimates, with consumer-tool changes applying from 2027 plan years.
Read the update →Briefing published 8 October 2026FDA Approves a New Maintenance Regimen for HER2-Positive Breast Cancer
The October 7 US approval of tucatinib with trastuzumab and pertuzumab for maintenance treatment after induction therapy in specified adults with advanced HER2-positive breast cancer.
Read the update →Briefing published 7 October 2026FDA Approves Expandable Pediatric Heart Valve; EMA Plans Women’s Health Roadmap
The FDA’s October 1 pediatric heart valve approval and EMA’s September 30 announcement of a planned women’s health medicines roadmap.
Read the update →Prepared by China Heal Plus. These briefings provide general information, not individual medical advice.
Research & reading briefs · Patient guides · Ask about a specialist review